Organovo Holdings, Inc. last week had its common shares approved to list on the NYSE MKT and began trading on the New York Stock Exchange on July 11, 2013, under the name “ONVO.” The NYSE is believed to be the premier US equities market for listing and trading of small growth companies. Organovo, a pioneering biotechnology company focused on delivering breakthrough 3D bioprinting technology, has now withdrawn its shares from listing on the OTC QX.
Keith Murphy, President and CEO of Organovo had this to say about the stock market transition: “Trading on the New York Stock Exchange is an important milestone for Organovo and will be valuable to our business and shareholders. Our decision to move to the NYSE MKT was based on a firm belief that the exchange offers the best set of conditions for Organovo’s success, and thus the best opportunity to add value for our shareholders. We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange.”
And in honour of the transition, at the start of this week’s trading, Organovo rang the opening bell on the NYSE.